MISC

査読有り 国際誌
2019年1月26日

Isolation and Characterization of Human Umbilical Cord-derived Mesenchymal Stem Cells from Preterm and Term Infants.

Journal of visualized experiments : JoVE
  • Sota Iwatani
  • ,
  • Makiko Yoshida
  • ,
  • Keiji Yamana
  • ,
  • Daisuke Kurokawa
  • ,
  • Jumpei Kuroda
  • ,
  • Khin Kyae Mon Thwin
  • ,
  • Suguru Uemura
  • ,
  • Satoru Takafuji
  • ,
  • Nanako Nino
  • ,
  • Tsubasa Koda
  • ,
  • Masami Mizobuchi
  • ,
  • Masahiro Nishiyama
  • ,
  • Kazumichi Fujioka
  • ,
  • Hiroaki Nagase
  • ,
  • Ichiro Morioka
  • ,
  • Kazumoto Iijima
  • ,
  • Noriyuki Nishimura

143
143
開始ページ
e58806
終了ページ
記述言語
英語
掲載種別
記事・総説・解説・論説等(学術雑誌)
DOI
10.3791/58806

Mesenchymal stem cells (MSCs) have considerable therapeutic potential and attract increasing interest in the biomedical field. MSCs are originally isolated and characterized from bone marrow (BM), then acquired from tissues including adipose tissue, synovium, skin, dental pulp, and fetal appendages such as placenta, umbilical cord blood (UCB), and umbilical cord (UC). MSCs are a heterogeneous cell population with the capacity for (1) adherence to plastic in standard culture conditions, (2) surface marker expression of CD73+/CD90+/CD105+/CD45-/CD34-/CD14-/CD19-/HLA-DR- phenotypes, and (3) trilineage differentiation into adipocytes, osteocytes, and chondrocytes, as currently defined by the International Society for Cellular Therapy (ISCT). Although BM is the most widely used source of MSCs, the invasive nature of BM aspiration ethically limits its accessibility. Proliferation and differentiation capacity of MSCs obtained from BM generally decline with the age of the donor. In contrast, fetal MSCs obtained from UC have advantages such as vigorous proliferation and differentiation capacity. There is no ethical concern for UC sampling, as it is typically regarded as medical waste. Human UC starts to develop with continuing growth of the amniotic cavity at 4-8 weeks of gestation and keeps growing until reaching 50-60 cm in length, and it can be isolated during the whole newborn delivery period. To gain insight into the pathophysiology of intractable diseases, we have used UC-derived MSCs (UC-MSCs) from infants delivered at various gestational ages. In this protocol, we describe the isolation and characterization of UC-MSCs from fetuses/infants at 19-40 weeks of gestation.

リンク情報
DOI
https://doi.org/10.3791/58806
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/30741254

エクスポート
BibTeX RIS